Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia

Author(s):  Cote Brianna, Ross Bethany, Fortner Jeff, Rao Deepa

Issue:  May/Jun 2018 - Volume 22, Number 3
View All Articles in Issue

Page(s):  252-256

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Page 1
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Page 2
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Page 3
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Page 4
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Page 5

Download in electronic PDF format for $75

Abstract:  Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive dysfunction. With few U.S. Food and Drug Administration-approved treatment options, there is evidence that low-dose naltrexone, an opioid antagonist approved for opioid and alcohol dependence at high doses, may have efficacy in the treatment of fibromyalgia and chronic pain. At the doses required for fibromyalgia treatment, naltrexone needs to be compounded, and no data currently exists regarding the long-term stability of low-dose naltrexone capsules. This limits pharmacies to a maximum beyond-use date of 180 days. Our study examined the stability of compounded capsules of low-dose naltrexone in Avicel over 360 days. Naltrexone was extracted from compounded capsules and assessed using reversed-phase high-performance liquid chromatography validated to differentiate between the degraded and undegraded naltrexone. United States Pharmacopeia guidelines state that compounded medications must remain within 10% of the labeled potency at all times during the assigned expiration date for a preparation. Our results show that low-dose naltrexone is stable for 360 days when stored at room temperature and away from light remaining within 90% to 110% of the labeled potency throughout the study period. Based on our study results, the beyond-use date for compounded low-dose naltrexone formulations stored at room temperature and protected from light can be extended to 1 year. The longer beyond-use dating allows patients greater flexibility in using these capsules during the flare-ups associated with fibromyalgia without needing a refill immediately at the onset of symptoms. In addition, it may help compounding pharmacies reduce waste associated with small-batch preparation of these capsules.

Related Keywords: Brianna Cote, PharmD, Bethany Ross, BS, Jeff Fortner, PharmD, Deepa Rao, PhD, naltrexone, fibromyalgia, chronic musculoskeletal pain, competitive opioid antagonist, chemical stability

Related Categories: MENTAL HEALTH, PAIN MANAGEMENT, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, MUSCULOSKELETAL DISORDERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna
, Ross Bethany, Fortner Jeff, Rao Deepa
May/Jun 2018
Pg. 252-256

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M
, Collin Michael
May/Jun 2016
Pg. 197-201

Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin
, Carvalho Maria, Banov Fabiana
Nov/Dec 2023
Pg. 468-473

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George
, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jul/Aug 2018
Pg. 270-278

Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B
, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020
Pg. 94-96

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer
, Weinstock Leonard B, Thomas Erin
Mar/Apr 2010
Pg. 171-173

The Role of Sex Hormones on Fibromyalgia Pain Mediators
Bramwell Bethany L
May/Jun 2010
Pg. 193-199

Naltrexone Hydrochloride 50-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 235

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff
, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Sep/Oct 2015
Pg. 414-419

Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
Mar/Apr 2019
Pg. 157-162

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike
, Kaiser Joe
Jul/Aug 2023
Pg. 284-293

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2024
Pg. 111-116

Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Jones Marty
Jan/Feb 2002
Pg. 4-6

Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension
Allen Loyd V Jr
May/Jun 2021
Pg. 233

Compounding Naltrexone for the Treatment of Autism
Wynn Tom
, Brunetti Sarah
Jul/Aug 2009
Pg. 296-299

Chemical Stability of Naltrexone Hydrochloride Injection
Gupta Vishnu D
May/Jun 2008
Pg. 274-275

Development and Validation of a Stability-indicating High-performance Liquid Chromatographic Method for Quantification of Progesterone in Compounded Glycerinated Gelatin Troches
Burrows Anna C
, Yellepeddi Venkata Kashyap, Snyder Spencer, Wakefield Meagan, Jackson David, Huynh Johnny, Nguyen Khoa, Sayre Casey L
Jul/Aug 2019
Pg. 340-350

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

Case Reports on the Use of Aloe Vera, Naltrexone, and Topiramate for the Treatment of Scars
Harris Kylie
, Wright Edward
Nov/Dec 2021
Pg. 482-485

Return to Top